The molecular cytology firm Veracyte Inc. arose in 2008 out of Calderome, an incubator formed by West Coast venture capital firms Kleiner Perkins Caufield & Byers (KPCB), TPG, and Versant Ventures. As they did with their other endeavors in molecular diagnostics in the 2000s, the VCs emphasized the need to understand the pharmacoeconomics of a potential new diagnostic test early on and to have a clear vision of how the test could influence clinical decision making.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?